P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

EBioMedicine

Volumn 3, Issue , 2016, Pages 54-66

  Katayama, Ryohei ^a   Sakashita, Takuya ^a,b   Yanagitani, Noriko ^c   Ninomiya, Hironori ^d   Horiike, Atsushi ^c   Friboulet, Luc ^e   Gainor, Justin F ^e   Motoi, Noriko ^d   Dobashi, Akito ^d   Sakata, Seiji ^d   Tambo, Yuichi ^c   Kitazono, Satoru ^c   Sato, Shigeo ^a   Koike, Sumie ^a   John Iafrate, A ^e   Mino Kenudson, Mari ^e   Ishikawa, Yuichi ^d   Shaw, Alice T ^e   Engelman, Jeffrey A ^e   Takeuchi, Kengo ^d   Nishio, Makoto ^c   Fujita, Naoya ^a   more..

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d CANCER INSTITUTE   (Japan)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ALK; Ceritinib; Crizotinib; P glycoprotein; Resistance; Tyrosine kinase

Indexed keywords

5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CERITINIB; CISPLATIN; CRIZOTINIB; DOCETAXEL; DOFEQUIDAR; LORLATINIB; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PEMETREXED; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOPSY; CASE REPORT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ANALYSIS; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG ADENOCARCINOMA; MOUSE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODEL; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION; THORAX RADIOGRAPHY; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; P-GLYCOPROTEIN; PROTEIN KINASE INHIBITORS; RADIOGRAPHY, THORACIC; RECEPTOR PROTEIN-TYROSINE KINASES; TOMOGRAPHY, X-RAY COMPUTED; TRANSLOCATION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958864602     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.12.009     Document Type: Article

References (44)

1. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K.P., Hughes T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99(9):3472-3475.
2. Chiba T., Kita K., Zheng Y.W., Yokosuka O., Saisho H., Iwama A., Nakauchi H., Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44(1):240-251.
3. Chuan Tang S., Nguyen L.N., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int. J. Cancer 2014, 134(6):1484-1494.
4. Costa D.B., Kobayashi S., Pandya S.S., Yeo W.L., Shen Z., Tan W., Wilner K.D. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol. 2011, 29(15):e443-e445.
5. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., Kondo K.L., Linderman D.J., Heasley L.E., Franklin W.A., Varella-Garcia M., Camidge D.R. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012, 18(5):1472-1482.
6. Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2008, 14(10):2895-2899.
7. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., Zhao F., Vincent P.W., Naumov G.N., Bradner J.E., Althaus I.W., Gandhi L., Shapiro G.I., Nelson J.M., Heymach J.V., Meyerson M., Wong K.K., Janne P.A. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007, 67(24):11924-11932.
8. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
9. FitzGerald D.J., Willingham M.C., Cardarelli C.O., Hamada H., Tsuruo T., Gottesman M.M., Pastan I. A monoclonal antibody-pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc. Natl. Acad. Sci. U. S. A. 1987, 84(12):4288-4292.
10. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10(2):147-156.
11. Friboulet L., Li N., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., Michellys P.Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C., Li J., Kasibhatla S., Sun F., Sun X., Hua S., McNamara P., Mahmood S., Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T., Engelman J.A. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014, 4(6):662-673.
12. Gadgeel S.M., Gandhi L., Riely G.J., Chiappori A.A., West H.L., Azada M.C., Morcos P.N., Lee R.M., Garcia L., Yu L., Boisserie F., Di Laurenzio L., Golding S., Sato J., Yokoyama S., Tanaka T., Ou S.H. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014.
13. Gainor J.F., Varghese A.M., Ou S.H., Kabraji S., Awad M.M., Katayama R., Pawlak A., Mino-Kenudson M., Yeap B.Y., Riely G.J., Iafrate A.J., Arcila M.E., Ladanyi M., Engelman J.A., Dias-Santagata D., Shaw A.T. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin. Cancer Res. 2013, 19(15):4273-4281.
14. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996, 183(4):1797-1806.
15. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2(1):48-58.
16. Haraguchi N., Utsunomiya T., Inoue H., Tanaka F., Mimori K., Barnard G.F., Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24(3):506-513.
17. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., Goodell M.A., Brenner M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(39):14228-14233.
18. Johnson T.W., Richardson P.F., Bailey S., Brooun A., Burke B.J., Collins M.R., Cui J.J., Deal J.G., Deng Y.L., Dinh D., Engstrom L.D., He M., Hoffman J., Hoffman R.L., Huang Q., Kania R.S., Kath J.C., Lam H., Lam J.L., Le P.T., Lingardo L., Liu W., McTigue M., Palmer C.L., Sach N.W., Smeal T., Smith G.L., Stewart A.E., Timofeevski S., Zhu H., Zhu J., Zou H.Y., Edwards M.P. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J. Med. Chem. 2014, 57(11):4720-4744.
19. Katayama R., Koike S., Sato S., Sugimoto Y., Tsuruo T., Fujita N. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Cancer Sci. 2009, 100(11):2060-2068.
20. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., Jessop N.A., Wain J.C., Yeo A.T., Benes C., Drew L., Saeh J.C., Crosby K., Sequist L.V., Iafrate A.J., Engelman J.A. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 2012, 4(120):120ra17.
21. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352(8):786-792.
22. Kodama T., Tsukaguchi T., Hasegawa M., Yoshida M., Takanashi K., Kondoh O., Sakamoto H. Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases. AACR Annual Meeting 2014, 74:754.
23. Kondo T., Setoguchi T., Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(3):781-786.
24. Kort A., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol. Res. 2015, 102:200-207.
25. Lovly C.M., McDonald N.T., Chen H., Ortiz-Cuaran S., Heukamp L.C., Yan Y., Florin A., Ozretic L., Lim D., Wang L., Chen Z., Chen X., Lu P., Paik P.K., Shen R., Jin H., Buettner R., Ansen S., Perner S., Brockmann M., Bos M., Wolf J., Gardizi M., Wright G.M., Solomon B., Russell P.A., Rogers T.M., Suehara Y., Red-Brewer M., Tieu R., de Stanchina E., Wang Q., Zhao Z., Johnson D.H., Horn L., Wong K.K., Thomas R.K., Ladanyi M., Pao W. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med. 2014, 20(9):1027-1034.
26. Marsilje T.H., Pei W., Chen B., Lu W., Uno T., Jin Y., Jiang T., Kim S., Li N., Warmuth M., Sarkisova Y., Sun F., Steffy A., Pferdekamper A.C., Li A.G., Joseph S.B., Kim Y., Liu B., Tuntland T., Cui X., Gray N.S., Steensma R., Wan Y., Jiang J., Chopiuk G., Li J., Gordon W.P., Richmond W., Johnson K., Chang J., Groessl T., He Y.Q., Phimister A., Aycinena A., Lee C.C., Bursulaya B., Karanewsky D.S., Seidel H.M., Harris J.L., Michellys P.Y. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J. Med. Chem. 2013, 56(14):5675-5690.
27. Naito M., Matsuba Y., Sato S., Hirata H., Tsuruo T. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin. Cancer Res. 2002, 8(2):582-588.
28. Nakanishi O., Baba M., Saito A., Yamashita T., Sato W., Abe H., Fukazawa N., Suzuki T., Sato S., Naito M., Tsuruo T. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncol. Res. 1997, 9(2):61-69.
29. Omachi N., Shimizu S., Kawaguchi T., Tezuka K., Kanazu M., Tamiya A., Asami K., Okishio K., Kitaichi M., Atagi S. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib. J. Thorac. Oncol. 2014, 9(6):e40-e42.
30. Saeki T., Nomizu T., Toi M., Ito Y., Noguchi S., Kobayashi T., Asaga T., Minami H., Yamamoto N., Aogi K., Ikeda T., Ohashi Y., Sato W., Tsuruo T. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J. Clin. Oncol. 2007, 25(4):411-417.
31. Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Fukami T.A., Oikawa N., Tsukuda T., Ishii N., Aoki Y. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19(5):679-690.
32. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., Lathan C., Marcoux J.P., Du J., Okuda K., Capelletti M., Shimamura T., Ercan D., Stumpfova M., Xiao Y., Weremowicz S., Butaney M., Heon S., Wilner K., Christensen J.G., Eck M.J., Wong K.K., Lindeman N., Gray N.S., Rodig S.J., Janne P.A. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011, 71(18):6051-6060.
33. Sato W., Fukazawa N., Nakanishi O., Baba M., Suzuki T., Yano O., Naito M., Tsuruo T. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother. Pharmacol. 1995, 35(4):271-277.
34. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., Hida T., Yamamoto N., Yoshioka H., Harada M., Ohe Y., Nogami N., Takeuchi K., Shimada T., Tanaka T., Tamura T. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013, 14(7):590-598.
35. Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future. J. Clin. Oncol. 2013, 31(8):1105-1111.
36. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., Wu Y.L., Thomas M., O'Byrne K.J., Moro-Sibilot D., Camidge D.R., Mok T., Hirsh V., Riely G.J., Iyer S., Tassell V., Polli A., Wilner K.D., Janne P.A. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368(25):2385-2394.
37. Shaw A.T., Kim D.W., Mehra R., Tan D.S., Felip E., Chow L.Q., Camidge D.R., Vansteenkiste J., Sharma S., De Pas T., Riely G.J., Solomon B.J., Wolf J., Thomas M., Schuler M., Liu G., Santoro A., Lau Y.Y., Goldwasser M., Boral A.L., Engelman J.A. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014, 370(13):1189-1197.
38. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
39. Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., Iyer S., Reisman A., Wilner K.D., Tursi J., Blackhall F., Investigators P. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371(23):2167-2177.
40. Sugimoto Y., Roninson I.B., Tsuruo T. Decreased expression of the amplified MDR1 gene in revertants of multidrug-resistant human myelogenous leukemia K562 occurs without loss of amplified DNA. Mol. Cell. Biol. 1987, 7(12):4549-4552.
41. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., Takada S., Ueno T., Yamashita Y., Satoh Y., Okumura S., Nakagawa K., Ishikawa Y., Mano H. KIF5B-ALK, a novel fusion on cokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 2009, 15(9):3143-3149.
42. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981, 41(5):1967-1972.
43. Wang K., Li M., Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010, 38(16):e164.
44. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7(9):1028-1034.